RIPK1表达与人类早期动脉粥样硬化炎症相关,沉默RIPK1可减少小鼠NF-κB激活和动脉粥样硬化
研究探讨RIPK1在动脉粥样硬化中的作用,发现RIPK1在人和小鼠早期斑块中高表达;在Apoe-/-小鼠中给予RIPK1反义寡核苷酸可减少斑块面积和血浆炎症因子,机制涉及抑制NF-κB通路,提示RIPK1是未来治疗靶点。
要点
- RIPK1在人和小鼠早期动脉粥样硬化斑块中高表达。
- RIPK1反义寡核苷酸减少Apoe-/-小鼠斑块面积和血浆炎症因子。
- RIPK1通过激活NF-κB通路驱动动脉粥样硬化炎症。
核心结论
- RIPK1通过激活NF-κB通路和促进炎症因子释放,是动脉粥样硬化炎症的核心驱动因素,提示其作为未来治疗靶点以减少高危冠心病患者的残余炎症。
研究设计与样本
- 检查人和小鼠动脉粥样硬化病变中RIPK1蛋白和mRNA表达,并在巨噬细胞和内皮细胞中进行体外功能缺失实验。
- 对喂食胆固醇丰富(西方)饮食8周的Apoe-/-小鼠每周注射RIPK1反义寡核苷酸。
主要发现
- RIPK1在人和小鼠早期动脉粥样硬化病变中表达丰富。
- 与对照相比,RIPK1反义寡核苷酸治疗使主动脉窦和整体病变面积减少47.2%或58.8%(P<0.01),并降低血浆炎症细胞因子IL-1α、IL-17A(P<0.05)。
- 在巨噬细胞中敲低RIPK1降低炎症基因(NF-κB、TNFα、IL-1α)以及体内脂多糖和致动脉粥样硬化饮食诱导的NF-κB激活。
- 在内皮细胞中,敲低RIPK1阻止TNFα诱导的NF-κB核转位,并减少IL1B、E-selectin基因表达和单核细胞黏附。
临床怎么用
- RIPK1可能作为未来治疗靶点,用于减少高危冠心病患者的残余炎症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic activation of the innate immune system drives inflammation and contributes directly to atherosclerosis. We previously showed that macrophages in the atherogenic plaque undergo RIPK3 (receptor-interacting serine/threonine-protein kinase 3)-MLKL (mixed lineage kinase domain-like protein)-dependent programmed necroptosis in response to sterile ligands such as oxidized low-density lipoprotein and damage-associated molecular patterns and that necroptosis is active in advanced atherosclerotic plaques. Upstream of the RIPK3-MLKL necroptotic machinery lies RIPK1 (receptor-interacting serine/threonine-protein kinase 1), which acts as a master switch that controls whether the cell undergoes NF-κB (nuclear factor κ-light-chain-enhancer of activated B cells)-dependent inflammation, caspase-dependent apoptosis, or necroptosis in response to extracellular stimuli. We therefore set out to investigate the role of RIPK1 in the development of atherosclerosis, which is driven largely by NF-κB-dependent inflammation at early stages. We hypothesize that, unlike RIPK3 and MLKL, RIPK1 primarily drives NF-κB-dependent inflammation in early atherogenic lesions, and knocking down RIPK1 will reduce inflammatory cell activation and protect against the progression of atherosclerosis. METHODS: We examined expression of RIPK1 protein and mRNA in both human and mouse atherosclerotic lesions, and used loss-of-function approaches in vitro in macrophages and endothelial cells to measure inflammatory responses. We administered weekly injections of RIPK1 antisense oligonucleotides to Apoe-/- mice fed a cholesterol-rich (Western) diet for 8 weeks. RESULTS: We find that RIPK1 expression is abundant in early-stage atherosclerotic lesions in both humans and mice. Treatment with RIPK1 antisense oligonucleotides led to a reduction in aortic sinus and en face lesion areas (47.2% or 58.8% decrease relative to control, P<0.01) and plasma inflammatory cytokines (IL-1α [interleukin 1α], IL-17A [interleukin 17A], P<0.05) in comparison with controls. RIPK1 knockdown in macrophages decreased inflammatory genes (NF-κB, TNFα [tumor necrosis factor α], IL-1α) and in vivo lipopolysaccharide- and atherogenic diet-induced NF-κB activation. In endothelial cells, knockdown of RIPK1 prevented NF-κB translocation to the nucleus in response to TNFα, where accordingly there was a reduction in gene expression of IL1B, E-selectin, and monocyte attachment. CONCLUSIONS: We identify RIPK1 as a central driver of inflammation in atherosclerosis by its ability to activate the NF-κB pathway and promote inflammatory cytokine release. Given the high levels of RIPK1 expression in human atherosclerotic lesions, our study suggests RIPK1 as a future therapeutic target to reduce residual inflammation in patients at high risk of coronary artery disease.
引用
- Karunakaran D, Nguyen MA, Geoffrion M, et al. RIPK1 Expression Associates With Inflammation in Early Atherosclerosis in Humans and Can Be Therapeutically Silenced to Reduce NF-κB Activation and Atherogenesis in Mice. Circulation. 2020. PMID: 33222501. doi:10.1161/CIRCULATIONAHA.118.038379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。